HONOLULU, April 7, 2008 /PRNewswire/ -- Hawaii Biotech announced today that it has received a grant from the Pediatric Dengue Vaccine Initiative (PDVI) to support the manufacture of Hawaii Biotech's dengue vaccine for eventual testing in clinical trials. Hawaii Biotech emphasized that it has not yet initiated regulatory filing for its dengue vaccine formulation.
Dengue is a mosquito-borne illness, prevalent in tropical and subtropical countries throughout the world. Approximately 3.5 billion people live in endemic countries and about 100 million people are infected with dengue every year according to recent estimates published by the PDVI. Infection by any one of the four dengue viruses can lead to dengue fever, which can progress to a life-threatening hemorrhagic fever and shock syndrome.
"PDVI conducted a thorough, independent evaluation of Hawaii Biotech's dengue vaccine program and believes their vaccine represents a promising candidate worthy of further development, which should lead to clinical evaluation," stated Dr. Harold Margolis, Director of the PDVI. "The Hawaii Biotech vaccine is the only subunit vaccine candidate against dengue that has advanced this far into pre-clinical development. We see the Hawaii Biotech vaccine as an important part of our portfolio of vaccines in our efforts to control this global public health problem."
"We appreciate the opportunity to collaborate with PDVI as we work to prevent disease caused by these debilitating viruses," said Dr. Elliot Parks of Hawaii Biotech. "We are also excited to be able to be part of an effort to control this disease, which occurs primarily in countries less developed than the United States."
PDVI is located at the International Vaccine Institute (IVI) in Seoul,
Korea. IVI is the world's only international organization solely dedicated
to vaccine research and development. Dr. John Clemens, Director General of
IVI, commented, "The IVI is committed to ensuring availab
|SOURCE Hawaii Biotech, Inc.|
Copyright©2008 PR Newswire.
All rights reserved